Literature DB >> 28224287

Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.

Gesine B Szurman1, Carsten H Meyer2, Nicolas Feltgen3, Amelie Pielen4, Bernhard Spitzer5, Matus Rehak6, Georg Spital7, Spyridon Dimopoulos8, Peter Szurman1, Kai Januschowski9,10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28224287     DOI： 10.1007/s00417-017-3618-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  3 in total

1.  Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicentre study.

Authors:  Gesine B Szurman; Kai Januschowski; Peter Szurman; Nicolas Feltgen; Bernhard Spitzer; Amelie Pielen; Matus Rehak; Georg Spital; Spyridon Dimopoulos; Carsten H Meyer
Journal:  Acta Ophthalmol       Date:  2016-02-01       Impact factor: 3.761

2.  Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicenter study.

Authors:  Kai Januschowski; Spyridon Dimopoulos; Peter Szurman; Nicolas Feltgen; Bernhard Spitzer; Amelie Pielen; Matus Rehak; Georg Spital; Carsten H Meyer; Gesine B Szurman
Journal:  Acta Ophthalmol       Date:  2015-01-25       Impact factor: 3.761

3.  Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.

Authors:  David L Epstein; Peep V Algvere; Gunvor von Wendt; Stefan Seregard; Anders Kvanta
Journal:  Ophthalmology       Date:  2012-08-17       Impact factor: 12.079
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.